Quantbot Technologies LP Inhibrx, Inc. Transaction History

Quantbot Technologies LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$18.45 - $27.14 $137,507 - $202,274	-7,453 Reduced 93.16%	547 $10,000
Q4 2022 Feb 13, 2023	BUY	$20.18 - $33.33 $161,440 - $266,640	8,000 New	8,000 $197,000
Q2 2022 Aug 09, 2022	BUY	$8.52 - $25.26 $23,983 - $71,106	2,815 Added 90.81%	5,915 $67,000
Q1 2022 May 16, 2022	BUY	$19.89 - $43.18 $37,791 - $82,042	1,900 Added 158.33%	3,100 $69,000
Q4 2021 Feb 11, 2022	BUY	$26.75 - $46.02 $32,100 - $55,224	1,200 New	1,200 $52,000

51.7K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $606M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

Stay updated on Quantbot Technologies LP with notifications on news.